Pfizer Inc. (NYSE:PFE) Shares Sold by Walled Lake Planning & Wealth Management LLC

Walled Lake Planning & Wealth Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 68.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 40,987 shares of the biopharmaceutical company’s stock after selling 88,666 shares during the quarter. Walled Lake Planning & Wealth Management LLC’s holdings in Pfizer were worth $1,087,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. United Bank lifted its holdings in shares of Pfizer by 27.3% in the fourth quarter. United Bank now owns 45,331 shares of the biopharmaceutical company’s stock valued at $1,203,000 after buying an additional 9,732 shares during the period. Life Planning Partners Inc bought a new stake in Pfizer in the fourth quarter worth about $893,000. Summit Securities Group LLC boosted its position in shares of Pfizer by 38.4% during the 4th quarter. Summit Securities Group LLC now owns 23,800 shares of the biopharmaceutical company’s stock valued at $631,000 after purchasing an additional 6,600 shares in the last quarter. Schroder Investment Management Group raised its holdings in shares of Pfizer by 13.6% in the 4th quarter. Schroder Investment Management Group now owns 9,973,310 shares of the biopharmaceutical company’s stock worth $264,592,000 after purchasing an additional 1,193,722 shares in the last quarter. Finally, American Money Management LLC acquired a new position in Pfizer in the fourth quarter worth approximately $211,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.8 %

Shares of NYSE PFE opened at $25.20 on Friday. The stock has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The business has a 50 day simple moving average of $26.06 and a 200 day simple moving average of $26.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.